GT-719

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameGT-719
Drug Alias NameGT719GT-719
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Chimeric antigen receptor NKT cell therapyCell and gene therapy > Cell therapy > Source of cells > Hematopoietic stem cell-derivedCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsPodocytopathiesAutoimmune DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator Companiesshenzhen Grit Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active Companiesshenzhen Grit Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPodocytopathiesAutoimmune DiseasesAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A